sulfo-Cyanine7 amine
| Cat. # | Quantity | Price | Lead time | Buy this product |
|---|---|---|---|---|
| 153C0 | 1 mg |
$125.00
|
in stock | |
| 253C0 | 5 mg |
$285.00
|
in stock | |
| 453C0 | 25 mg |
$680.00
|
in stock | |
| 553C0 | 50 mg |
$1260.00
|
in stock | |
| 653C0 | 100 mg |
$1990.00
|
5 days |
Sulfonated amino derivative of Cyanine7 NIR dye.
This NIR dye amine can be used for the derivatization of various targets by the reaction with electrophilic groups, and also by enzymatical reactions involving transamination.
Sulfo-Cyanine7 absorbance and emission spectra
Customers also purchased with this product
General properties
| Appearance: | dark green powder |
| Molecular weight: | 807.07 |
| CAS number: | 2236573-39-8 |
| Molecular formula: | C43H58N4O7S2 |
| Solubility: | very poorly soluble in water (0.50 mM = 40 mg/L), good in DMF, DMSO |
| Quality control: | NMR 1H, HPLC-MS (95%) |
| Storage conditions: | Storage: 24 months after receival at -20°C in the dark. Transportation: at room temperature for up to 3 weeks. Avoid prolonged exposure to light. |
| MSDS: | Download |
| Product specifications |
Spectral properties
| Excitation/absorption maximum, nm: | 750 |
| ε, L⋅mol−1⋅cm−1: | 240600 |
| Emission maximum, nm: | 773 |
| Fluorescence quantum yield: | 0.24 |
| CF260: | 0.04 |
| CF280: | 0.04 |
Product citations
- Liu, L.; Li, X.; Wu, Z.; Yang, L.; Huo, J.; Tang, S.; Cao, X.; Xu, Y.; Liao, X.; Qi, H.; Li, J.; Liu, J.; Tian, J.; Wen, R.; Wang, C.; Bai, C. Inflammation-targeting Fullerene Nanoparticles Dually Inhibit Macrophage and Osteoclast Differentiation for Mitigating Rheumatoid Arthritis. CCS Chemistry, 2024, 6(9), 2275-2288. doi: 10.31635/ccschem.023.202303517
- Grosskopf, A.K.; Correa, S.; Baillet, J.; Maikawa, C.L.; Gale, E.C.; Brown, R.A.; Appel, E.A. Consistent tumorigenesis with self-assembled hydrogels enables high-powered murine cancer studies. Communications Biology, 2021, 4, 985. doi: 10.1038/s42003-021-02500-8
- Kim, H.; Han, J.; Park, J.-H. Cyclodextrin polymer improves atherosclerosis therapy and reduces ototoxicity. Journal of Controlled Release, 2020, 319, 77–86. doi: 10.1016/j.jconrel.2019.12.021
- Rippe, M.; Stefanello, T.F.; Kaplum, V.; Britta, E.A.; Garcia, F.P.; Poirot, R.; Companhoni, M.V.P.; Nakamura, C.V.; Szarpak-Jankowska, A.; Auzély-Velty, R. Heparosan as a potential alternative to hyaluronic acid for the design of biopolymer-based nanovectors for anticancer therapy. Biomaterials Science, 2019, 7, 2850–2860. doi: 10.1039/c9bm00443b
Cy® is a trademark of GE Healthcare.
This Product is offered and sold for research purposes only. It has not been tested for safety and efficacy in food, drug, medical device, cosmetic, commercial or any other use. Supply does not express or imply authorization to use for any other purpose, including, without limitation, in vitro diagnostic purposes, in the manufacture of food or pharmaceutical products, in medical devices or in cosmetic products.
Short link - lumiprobe.com/sh/p/1Y
The count of items is incorrect.


$